Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 94.35
-3.85 (-3.92%)
Sep 10, 2026, 4:08 PM HKT
Innovent Biologics Market Cap
Innovent Biologics has a market cap or net worth of 164.26 billion as of September 10, 2026. Its market cap has decreased by -4.95% in one year.
Market Cap
164.26B
Enterprise Value
143.85B
Revenue
18.13B
Ranking
n/a
PE Ratio
117.44
Stock Price
94.35
ChartMarket Cap Chart
Since October 31, 2018, Innovent Biologics's market cap has increased from 18.54B to 164.26B, an increase of 786.00%. That is a compound annual growth rate of 31.96%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 10, 2026 | 164.26B | 24.19% |
| Dec 31, 2025 | 132.27B | 120.60% |
| Dec 31, 2024 | 59.96B | -13.32% |
| Dec 29, 2023 | 69.17B | 34.57% |
| Dec 30, 2022 | 51.40B | -27.14% |
| Dec 31, 2021 | 70.55B | -38.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Oct 31, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| BeOne Medicines AG | 313.38B |
| WuXi Biologics | 200.43B |
| Sichuan Kelun-Biotech Biopharmaceutical | 114.97B |
| Sino Biopharmaceutical | 99.91B |
| Akeso | 87.55B |
| Genscript Biotech | 73.65B |
| RemeGen | 64.76B |
| Biocytogen Pharmaceuticals (Beijing) | 56.25B |